Login with Linked

Follow us on

Link Linkedin Youtube

Izervay

Izervay is a monthly injection into the eye to treat geographic atrophy caused by age-related macular degeneration. It slows vision loss by targeting a key protein involved in retinal cell death.

Molecule Details :

  • Molecule Name :

    Avacincaptad Pegol

  • Innovator :

    IVERIC BIO INC

  • Approval Date :

    04-Aug-23

  • NCE-1 Date :

    04-Aug-27

  • NCE Date :

    04-Aug-28

  • Dosage Form :

    Intravitreal Solution

  • Strength :

    EQ 2MG BASE/0.1ML

  • Therapeutic Category :

    Ophthalmic

  • Revenue ($M) :

    382

Year-wise Projected Sales ($M) :

  • 2025 :

    584

  • 2026 :

    812

  • 2027 :

    1,026

  • 2028 :

    1,209

  • 2029 :

    1,418

  • 2030 :

    1,599

  • 2031 :

    1,775
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?